Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Int J Mol Med. 2018 May;41(5):2813-2831. doi: 10.3892/ijmm.2018.3513. Epub 2018 Feb 23.
Mounting evidence has shown that miR-23b-3p, which is associated with cell proliferation, invasion, and apoptosis, acts as a biomarker for diagnosis and outcomes in numerous cancers. However, the clinicopathological implication of miR-23b-3p in hepatocellular carcinoma (HCC) remains unclear. Our study evaluated the role of miR-23b-3p in HCC and investigated its potential application as a marker for preliminary diagnosis and therapy in HCC. High-throughput data from the NCBI Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) were collected and analyzed. One hundred and one tissue sections of HCC were paired with adjacent non-cancerous HCC as further supplements. miR-23b-3p expression was detected using quantitative real-time PCR. Additionally, the relationship between miR-23b-3p expression and HCC progression and Time-to-recurrence (months) was explored. Ten algorithms were applied to predict the prospective target genes of miR-23b-3p. Next, we conducted bioinformatics analysis for further study. miR-23b-3p expression was pronouncedly decreased in HCC tissues in contrast with their paired adjacent non-cancerous HCC (P<0.001) with RT-qPCR. In total, 405 targets, acquired with consistent prediction from at least five databases, were used for the bioinformatics analysis. According to the Gene Ontology (GO) analysis, all targets were classified into biological processes, cellular components and molecular functions. In the pathway analysis, targets of miR-23b-3p were primarily enriched in the signaling pathways of renal cell carcinoma, hepatitis B and pancreatic cancer (corrected P-value <0.05). In the protein-protein interaction (PPI) network for miR-23b-3p, a total of 8 targets, including SRC, AKT1, EGFR, CTNNB1, BCL2, SMAD3, PTEN and KDM6A, were located in the key nodes with high degree (>35). In conclusion, this study provides impressive illumination of the potential role of miR-23b-3p in HCC tumorigenesis and progression. Furthermore, miR-23b-3p may act as a predictor of HCC and could be a new treatment target.
越来越多的证据表明，miR-23b-3p 与细胞增殖、侵袭和凋亡有关，可作为许多癌症诊断和预后的生物标志物。然而，miR-23b-3p 在肝细胞癌 (HCC) 中的临床病理意义尚不清楚。我们的研究评估了 miR-23b-3p 在 HCC 中的作用，并研究了其作为 HCC 初步诊断和治疗标志物的潜在应用。从 NCBI Gene Expression Omnibus (GEO) 和 The Cancer Genome Atlas (TCGA) 收集了高通量数据，并进行了分析。收集了 101 个 HCC 组织切片，并进一步补充了配对的相邻非癌性 HCC。使用实时定量 PCR 检测 miR-23b-3p 的表达。此外，还探讨了 miR-23b-3p 表达与 HCC 进展和复发时间 (月) 的关系。应用 10 种算法预测 miR-23b-3p 的潜在靶基因。接下来，我们进行了生物信息学分析。与配对的相邻非癌性 HCC 相比，HCC 组织中 miR-23b-3p 的表达明显降低(P<0.001)，采用 RT-qPCR 进行检测。总共获得了 405 个靶标，这些靶标是从至少五个数据库的一致预测中获得的，用于生物信息学分析。根据基因本体论 (GO) 分析，所有靶标都分为生物过程、细胞成分和分子功能。在通路分析中，miR-23b-3p 的靶标主要富集在肾细胞癌、乙型肝炎和胰腺癌的信号通路中(校正 P 值<0.05)。在 miR-23b-3p 的蛋白质-蛋白质相互作用 (PPI) 网络中，共有 8 个靶标，包括 SRC、AKT1、EGFR、CTNNB1、BCL2、SMAD3、PTEN 和 KDM6A，位于高度度 (>35) 的关键节点。总之，本研究为 miR-23b-3p 在 HCC 肿瘤发生和进展中的潜在作用提供了令人印象深刻的启示。此外，miR-23b-3p 可能作为 HCC 的预测因子，并可能成为新的治疗靶点。
